EMERGENT BIOSOLUTIONS INC. Payments to Acquire Other Productive Assets
EMERGENT BIOSOLUTIONS INC. (EBS) reported Payments to Acquire Other Productive Assets of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireOtherProductiveAssets · last filed 2025-03-04
- EMERGENT BIOSOLUTIONS INC. payments to acquire other productive assets for the quarter ending 2023-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payments to acquire other productive assets for the quarter ending 2022-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payments to acquire other productive assets for the quarter ending 2021-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payments to acquire other productive assets for fiscal 2024 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payments to acquire other productive assets for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. payments to acquire other productive assets for fiscal 2022 was $243.70M.
- EMERGENT BIOSOLUTIONS INC. payments to acquire other productive assets for fiscal 2021 was $0.00.
| Period end | Payments to Acquire Other Productive Assets 3 month | Payments to Acquire Other Productive Assets 9 month | Payments to Acquire Other Productive Assets 12 month |
|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-04 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $0.00 10-K · filed 2025-03-04 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-12-11 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $243.70M 10-K · filed 2025-03-04 | |
| 2022-09-30 | $243.70M 10-Q · filed 2023-12-11 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $0.00 10-K · filed 2024-03-08 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | ||
| 2020-12-31 | $0.00 10-K/A · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |